Investors & Media

press releases

There are currently no events to display.
Date Title Teaser
01/07/19
Summary Togglebluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies CAMBRIDGE, Mass. & SAN DIEGO --(BUSINESS WIRE)--Jan. 7, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) and Inhibrx, Inc. (Inhibrx) today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using
01/03/19
Summary Togglebluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 37 th Annual J.P. Morgan Healthcare Conference , Tuesday, January 8 , at 2:30 p.m. PT at the Westin St.

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.

Media Contacts

Jenn Snyder

VP, Corporate Communications

(617) 448-0281

JSnyder@bluebirdbio.com

 

Catherine Falcetti

Senior Director, Corporate Communications

(339) 499-9436

CFalcetti@bluebirdbio.com

 

Investor Contact

Elizabeth Pingpank

Director, Corporate Communications

(617) 914-8736

EPingpank@bluebirdbio.com